MDS 2023 | Approved and emerging treatment options for transplant-ineligible patients with high-risk MDS
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses treatment options for patients with high-risk myelodysplastic syndromes (HR-MDS) who are not eligible for allogeneic stem cell transplantation (alloSCT). Prof. Platzbecker explains that at the moment, azacitidine is the only approved agent for these patients, and venetoclax is only approved in elderly patients with acute myeloid leukemia (AML). To conclude, Prof. Platzbecker looks forward to the results of the Phase III VERONA clinical trial (NCT04401748) comparing the efficacy of azacitidine versus azacitidine + venetoclax in patients with HR-MDS, which will clarify the role of this combination in transplant-ineligible patients. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
